Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623086 · ClinicalTrials.gov registry record · Phase 4
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
A Phase 4 study of Type 1 Diabetes, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT04623086 is a Phase 4 study of Type 1 Diabetes that has completed, run by University of Washington. The registered enrollment target is 59 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04623086, a Phase 4 study of Type 1 Diabetes, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of degludec.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Insulin Glargine
- DRUG Insulin Degludec
Study Locations (1)
Washington
- University of Washington Medicine Diabetes Institute at South Lake Union - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623086
The ClinicalTrials.gov registry entry for NCT04623086 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (93% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04623086 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04623086 about?
NCT04623086 is a clinical study titled "Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose". This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of deglude...
What is the current status of trial NCT04623086?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2020-02-14. Estimated completion is 2023-12-31.
What conditions does trial NCT04623086 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT04623086?
The interventions under investigation include: Placebo (DRUG), Insulin Glargine (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT04623086?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623086 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
RECRUITING · Phase 4
-
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
COMPLETED · Phase 4
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus
COMPLETED · Phase 4
-
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.